Effect of agalsidase alfa replacement therapy on fabry disease—related hypertrophic cardiomyopathy: A 12- to 36-month, retrospective, blinded echocardiographic pooled analysis

This publication has 44 references indexed in Scilit:

• Treatment of Anderson–Fabry disease
  Heart, 2008
• Impact of Enzyme Replacement Therapy on Cardiac Morphology and Function and Late Enhancement in Fabry’s Cardiomyopathy
  The American Journal of Cardiology, 2006
• The effect of 12‐month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease
  Journal of Inherited Metabolic Disease, 2006
• Prevalence and Clinical Significance of Cardiac Arrhythmia in Anderson-Fabry Disease
  The American Journal of Cardiology, 2005
• Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with α galactosidase A
  Heart, 2005
• The natural history of left ventricular systolic function in Anderson-Fabry disease
  Heart, 2005
• Electrophysiologic findings in Fabry's disease with a short PR interval
  The American Journal of Cardiology, 1994
• Detection of left ventricular hypertrophy by M-mode echocardiography. Anatomic validation, standardization, and comparison to other methods.
  Hypertension, 1987
• Echocardiographic abnormalities and disease severity in Fabry's disease
  JACC, 1986
• Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements.
  Circulation, 1978